Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and...

Area of Science:

• Pharmacovigilance
• Epidemiology
• Health Informatics

Background:

• The Sentinel Initiative, sponsored by the US Food and Drug Administration, monitors medical product safety using a distributed database.
• Evaluating the efficiency and accuracy of safety monitoring tools is crucial for timely public health interventions.

Purpose of the Study:

• To assess the Sentinel Propensity Score Matching Tool's capability to rapidly reproduce a known association between glyburide and glipizide with serious hypoglycemia.
• To validate the tool's performance across multiple data partners.

Main Methods:

• A cohort assessment was performed using data from 13 Sentinel data partners.
• The Sentinel Propensity Score Matching Tool was employed to analyze new users of glyburide versus glipizide.
• Propensity score matching was conducted using predefined variables, empirically selected variables (high-dimensional propensity score), and a combination of both.

Main Results:

• The study identified 198,550 new users of glyburide and 379,507 new users of glipizide.
• Propensity score matching demonstrated a hazard ratio (HR) of 1.36 (1.24, 1.49) for glyburide versus glipizide.
• High-dimensional propensity score methods yielded HRs of 1.49 (1.31, 1.70) and 1.51 (1.32, 1.71), confirming the association.

Conclusions:

• The Sentinel Propensity Score Matching Tool successfully reproduced the known association between glyburide and an increased risk of serious hypoglycemia compared to glipizide.
• The findings demonstrate the tool's ability to expedite the confirmation of drug safety signals within a large, distributed healthcare database.